Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Inhibitory Effects of Azelastine and Its Metabolites on Drug Oxidation Catalyzed by Human Cytochrome P-450 Enzymes

Miki Nakajima, Katsuhiro Ohyama, Sumika Nakamura, Noriaki Shimada, Hiroshi Yamazaki and Tsuyoshi Yokoi
Drug Metabolism and Disposition July 1999, 27 (7) 792-797;
Miki Nakajima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katsuhiro Ohyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sumika Nakamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noriaki Shimada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Yamazaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsuyoshi Yokoi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Azelastine, an antiallergy and antiasthmatic drug, has been reported to be metabolized mainly to desmethylazelastine and 6-hydroxyazelastine in mammals. In the present study, the inhibitory effects of azelastine and its two metabolites on human cytochrome P-450 (CYP) isoform-dependent reactions were investigated to predict the drug interactions of azelastine using microsomes from human B-lymphoblast cells expressing CYP. The specific activities for human CYP isoforms included: 7-ethoxyresorufin O-deethylation (CYP1A1), phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), 7-benzyloxyresorufinO-dealkylation (CYP2B6), S-warfarin 7-hydroxylation (CYP2C9), S-mephenytoin 4′-hydroxylation (CYP2C19), bufuralol 1′-hydroxylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and testosterone 6β-hydroxylation (CYP3A4). In almost all the activities, desmethylazelastine exhibited stronger inhibition than azelastine and 6-hydroxyazelastine. Desmethylazelastine, but not azelastine and 6-hydroxyazelastine, uncompetitively inhibited CYP2B6 activity (Ki = 32.6 ± 4.8 μM). Azelastine, desmethylazelastine, and 6-hydroxyazelastine competitively inhibited CYP2C9 activity (Ki = 13.9 ± 1.8, 15.0 ± 3.1, and 17.0 ± 4.1 μM, respectively), CYP2C19 activity (Ki = 21.9 ± 2.2, 7.3 ± 1.6, and 9.3 ± 1.6 μM, respectively), and CYP2D6 activity (Ki= 1.2 ± 0.1, 1.5 ± 0.2, and 3.0 ± 0.5 μM, respectively). Azelastine and desmethylazelastine competitively inhibited CYP3A4 activity (Ki = 23.7 ± 4.6 and 13.2 ± 2.3 μM). 6-Hydroxyazelastine interfered with the determination of testosterone 6β-hydroxylation by HPLC. CYP1A2, CYP2A6, and CYP2E1 activities were not significantly inhibited by azelastine and the two metabolites. Among the human CYPs tested, the inhibitory effects of azelastine and its two metabolites were the most potent on human CYP2D6. In consideration of theKi values and the concentration of azelastine and desmethylazelastine in human livers after chronic oral administration of azelastine, the possibility of in vivo drug interaction of azelastine and other drugs that are mainly metabolized by CYP2D6 was suggested although it might not cause critical side effects. The inhibition of CYP2C9, CYP2C19, and CYP3A4 activity by azelastine and its two metabolites might be clinically insignificant.

Footnotes

  • Send reprint requests to: Dr. Miki Nakajima, Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, Takara-machi 13–1, Kanazawa 920-0934, Japan. E-mail:nmiki{at}kenroku.kanazawa-u.ac.jp

  • Abbreviations used are::
    CYP
    cytochrome P-450
    BFOH
    bufuralol 1′-hydroxylase activity
    BROD
    7-benzyloxyresorufin O-dealkylase activity
    COH
    coumarin 7-hydroxylase activity
    CZXOH
    chlorzoxazone 6-hydroxylase activity
    EROD
    7-ethoxyresorufin O-deethylase activity
    POD
    phenacetin O-deethylase activity
    S-MPOH
    S-mephenytoin 4′-hydroxylase activity
    S-WFOH
    S-warfarin 7-hydroxylase activity
    TESOH
    testosterone 6β-hydroxylase activity
    • Received January 21, 1999.
    • Accepted March 30, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (7)
Drug Metabolism and Disposition
Vol. 27, Issue 7
1 Jul 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibitory Effects of Azelastine and Its Metabolites on Drug Oxidation Catalyzed by Human Cytochrome P-450 Enzymes
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inhibitory Effects of Azelastine and Its Metabolites on Drug Oxidation Catalyzed by Human Cytochrome P-450 Enzymes

Miki Nakajima, Katsuhiro Ohyama, Sumika Nakamura, Noriaki Shimada, Hiroshi Yamazaki and Tsuyoshi Yokoi
Drug Metabolism and Disposition July 1, 1999, 27 (7) 792-797;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inhibitory Effects of Azelastine and Its Metabolites on Drug Oxidation Catalyzed by Human Cytochrome P-450 Enzymes

Miki Nakajima, Katsuhiro Ohyama, Sumika Nakamura, Noriaki Shimada, Hiroshi Yamazaki and Tsuyoshi Yokoi
Drug Metabolism and Disposition July 1, 1999, 27 (7) 792-797;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics